We present an in vivo and in vitro study of congenital adrenal hyperplasia in a patient with 11␤-hydroxylase deficiency. Sequencing of the CYP11B1 gene showed two new base substitutions, a conservative 954 G3 C transversion at the last base of exon 5 (T318T), and a IVS8 ϩ 4A3 G transition in intron 8. In addition, two polymorphisms were found in exons 1 and 2. The genetically female patient was raised as a male because of severe pseudohermaphroditism. Glucocorticoid-suppressive treatment encountered difficulties in equilibration and compliance, resulting in uncontrolled hypertension with pronounced hypertrophic cardiomyopathy. At 42 yr of age the occurrence of central retinal vein occlusion with permanent loss of left eye vision led to the decision to perform bilateral laparoscopic adrenalectomy. Surgery was followed by normalization of blood pressure and good compliance with glucocorticoid and androgen substitutive therapies. In vitro, adrenal cells in culture and isolated mitochondria showed extremely low 11␤-hydroxylase activity. Analysis of adrenal CYP11B1 messenger ribonucleic acid (mRNA) by RT-PCR and sequencing showed the expression of a shorter mRNA that lacked exon 8 and did not contain either the exon 5 mutation or the exon 1 and 2 polymorphisms. This suggested that one CYP11B1 allele carried the intron 8 mutation, responsible for skipping exon 8. The other allele carried the exon 5 mutation, and its mRNA was not detectable. Western blot analysis showed weak expression of a shorter CYP11B immunoreactive band of 43 kDa, consistent with truncation of exon 8. Thus, bilateral adrenalectomy in this patient allowed effective treatment of severe hypertension and helped in understanding the mechanisms and physiopathological consequences of two novel mutations of CYP11B1. (J Clin Endocrinol Metab 85: 4060 -4068, 2000) C ONGENITAL ADRENAL hyperplasia (CAH) is a group of autosomal recessive disorders due to inactivating mutations in genes implicated in cortisol (F) synthesis. Steroid 11␤-hydroxylase deficiency, the second most common cause of CAH, is related to mutations of CYP11B1. As in the more frequent steroid 21-hydroxylase deficiency, steroid 11␤-hydroxylase deficiency is characterized by overproduction of adrenal androgens, which leads to virilization of the female fetus or pseudoprecocious puberty in male infants. In contrast to steroid 21-hydroxylase deficiency, however, untreated steroid 11␤-hydroxylase-deficient patients have no salt loss. On the contrary, they frequently present low renin hypertension related to overproduction of deoxycorticosterone (DOC) and possibly other precursors with mineralocorticoid activity. This hypertension can be severe (1-4). To date, all CYP11B1 mutations reported in steroid 11␤-hydroxylase deficiency are nonsense, frameshift, or missense exonic mutations (5), with the exception of one intronic mutation reported in the 5Ј-GT splice donor site of intron 5 (6).
apies. In vitro, adrenal cells in culture and isolated mitochondria showed extremely low 11␤-hydroxylase activity. Analysis of adrenal CYP11B1 messenger ribonucleic acid (mRNA) by RT-PCR and sequencing showed the expression of a shorter mRNA that lacked exon 8 and did not contain either the exon 5 mutation or the exon 1 and 2 polymorphisms. This suggested that one CYP11B1 allele carried the intron 8 mutation, responsible for skipping exon 8. The other allele carried the exon 5 mutation, and its mRNA was not detectable. Western blot analysis showed weak expression of a shorter CYP11B immunoreactive band of 43 kDa, consistent with truncation of exon 8. Thus, bilateral adrenalectomy in this patient allowed effective treatment of severe hypertension and helped in understanding the mechanisms and physiopathological consequences of two novel mutations of CYP11B1. (J Clin Endocrinol Metab 85: 4060 -4068, 2000) C ONGENITAL ADRENAL hyperplasia (CAH) is a group of autosomal recessive disorders due to inactivating mutations in genes implicated in cortisol (F) synthesis. Steroid 11␤-hydroxylase deficiency, the second most common cause of CAH, is related to mutations of CYP11B1. As in the more frequent steroid 21-hydroxylase deficiency, steroid 11␤-hydroxylase deficiency is characterized by overproduction of adrenal androgens, which leads to virilization of the female fetus or pseudoprecocious puberty in male infants. In contrast to steroid 21-hydroxylase deficiency, however, untreated steroid 11␤-hydroxylase-deficient patients have no salt loss. On the contrary, they frequently present low renin hypertension related to overproduction of deoxycorticosterone (DOC) and possibly other precursors with mineralocorticoid activity. This hypertension can be severe (1) (2) (3) (4) . To date, all CYP11B1 mutations reported in steroid 11␤-hydroxylase deficiency are nonsense, frameshift, or missense exonic mutations (5) , with the exception of one intronic mutation reported in the 5Ј-GT splice donor site of intron 5 (6) .
The established treatment of steroid 11␤-hydroxylase deficiency is similar to that of steroid 21-hydroxylase deficiency and consists of glucocorticoid-suppressive therapy and surgical correction of the ambiguous external genitalia in virilized female patients. Suppressive therapy seems at first glance perfectly adapted to the physiopathology of steroid 11␤-hydroxylase deficiency. Glucocorticoids substitute for F deficiency and inhibit ACTH oversecretion, which is the drive for excessive androgen and mineralocorticoid production. However, in CAH, effective suppression of ACTH requires supraphysiological doses of glucocorticoid, which explains why it is often difficult to maintain satisfactory adrenal suppression without producing an unacceptable degree of hypercortisolism (7) . Compliance is also a major concern, especially in adolescence and adulthood. As steroid 11␤-hydroxylase deficiency is relatively rare, large follow-up studies are not available. Nevertheless, complications of hypertension have been reported in both male and female patients (1, 4) . By comparison, patients with congenital adrenal insufficiency, which are only faced with substitution therapy, are generally believed to fare well, with normal stature, normal fertility, no androgen excess, and no hypertension (New, M. I., commentary in Ref. 8) . Therefore, in CAH, a contro-versy has arisen as to whether some patients with steroid 21-hydroxylase deficiency might benefit from bilateral adrenalectomy to be raised as Addisonians (7) . By contrast, in the less frequent steroid 11␤-hydroxylase deficiency, the option of bilateral adrenalectomy has rarely been discussed, and to our knowledge there has been only one report that illustrated its interest in the management of a 14-yr-old girl of unknown genetics, facing difficulties in suppressing androgen production (8) .
In the present work we report the use of laparoscopic bilateral adrenalectomy to treat severe hypertension in a 42-yr-old adult patient with steroid 11␤-hydroxylase deficiency, who had experienced long-term difficulties with equilibrium and compliance with suppressive therapy. Bilateral adrenalectomy allowed normalization of blood pressure and was followed by, to date, good compliance with the substitutive therapy. This patient carried two germline CYP11B1 base substitutions whose signification had remained speculative, as one was a conservative exonic mutation and the other was an intronic mutation. Analysis of the patient macronodular adrenals showed that they had very low 11␤-hydroxylase activity and only expressed a CYP11B1 messenger ribonucleic acid (mRNA), which lacked one exon, and a low amount of a truncated CYP11B1 protein. Thus, this study allowed us to understand the significance of two previously undescribed CYP11B1 mutations and raises the possibility of bilateral adrenalectomy for the treatment of some patients carrying severe mutations in CYP11B1.
Subject and Methods

Case report
The patient was born in 1953 and was raised as a male. At 20 months of age, development of pubic hair lead to the diagnosis of pseudoprecocious puberty in an XX female with pseudohermaphroditism (stage IV of Prader). Bone age was 6.5 yr, and systolic blood pressure was 105 mm Hg. An iv pyelogram with retropneumoperitoneum showed bilateral hyperplastic adrenals. Urinary 17-ketosteroid levels were elevated (7.6 mg/day; normal, Ͻ2.3 mg/day). The patient had a brother who had presented with signs of precocious puberty and died at 6.5 yr of age, probably of brain hemorrhage. Suppressive treatment was initiated at 21 months of age with 30 mg hydrocortisone, followed by various dosages of prednisone. At 4 yr of age, after psychological evaluation, the decision was made to follow the parents' desire to raise the child as a boy. Bilateral ovariectomy was performed. In childhood, suppressive treatment was difficult to equilibrate, with periods of high blood pressure (up to 150/90 mm Hg, with headaches and blurred vision) and hyperandrogenism and periods of good control of blood pressure, but hypoandrogenism and development of Cushingoid features. At 14 yr, chronological age reached bone age. Androgen substitutive therapy was added, allowing completion of virilization. Final height was only 146 cm. At 16 yr of age, explorations performed after interruption of treatment and on a regular salt intake showed suppressed renin activity (5 ng/L⅐min; normal, 90 Ϯ 30) and a very high DOC secretion rate (22.9 mg/day). Both were normalized by glucocorticoid-suppressive treatment, confirming the diagnosis of 11␤-hydroxylase deficiency. In adolescence, suppressive treatment was complicated by weight gain of up to 70 kg (body mass index, 33), with development of Cushingoid features, including striaes. The patient was married at 24 yr of age, but divorced 2 yr later and then abandoned all treatment for 18 yr even though he knew his systolic blood pressure was chronically around 180 mm Hg. He was also a heavy smoker, and he later proved to have a high salt intake.
At 42 yr of age, sudden loss of vision of the left eye lead to the diagnosis of central retinal vein occlusion. Blood pressure was 200/100 mm Hg, and kaliemia was 2.4 mmol/L (n ϭ 3.5-5). Weight was 51 kg (body mass index, 24), and there was no dyslipidemia or diabetes. Echocardiogram showed pronounced concentric ventricular hypertrophy (septum wall, 16 -20 mm; posterior wall, 12-14 mm; n ϭ 10 mm) consistent with uncontrolled hypertension of long duration. Serum creatinine was normal. An abdominal computed tomography scan showed large bilateral macronodular adrenal hyperplasia (left gland, 55 ϫ 50 ϫ 30 mm; right gland, 48 ϫ 25 ϫ 12 mm; Fig. 1A) .
Restoration of suppressive therapy with 7.5 mg/day prednisone and antihypertensive therapy with nicardipine (100 mg/day) allowed suppression of 11-deoxycortisol (S) and DOC levels and normalization of kaliemia and blood pressure. However, it proved very difficult to maintain this good control. Due to the reappearance of weight gain up to 60 kg and Cushingoid features, the patient decided himself to lower prednisone dosage to 5 mg/day, followed by a rise in blood pressure and the reappearance of hypokaliemia. Spironolactone (150 mg/day) was tried, but had to be stopped because of impotence. Central retinal venous occlusion was treated by systemic heparin therapy, vasodilators, and local injection of corticoids (which initially contributed to ACTH suppression). Evolution was marked by persistent macular edema and macular microhemorrhagia, requiring laser photocoagulation. After 1 yr of treatment, left eye vision was only 1.5/10, indicating permanent optic nerve damage, which suggested that the occlusion had actually been mixed, venous and arterial.
Because of the difficulties with suppressive treatment, the poor control of blood pressure, and the risk of more ophthalmological and cardiovascular complications, the option of bilateral adrenalectomy was then discussed with the patient. Special emphasis was placed on the postoperative life-time requirement for both a vital substitutive therapy with hydrocortisone and an androgen substitutive therapy. The patient volunteered for surgery, which was performed at 44 yr of age, using an abdominal laparoscopic approach with a lateral decubitus position. The two adrenals were removed successively in the same operation, which lasted 3 h, including repositioning of the patient after the first adrenalectomy. No complications occurred, intestinal mobility was restored on the second postoperative day, and the patient was discharged from the hospital on the fourth postoperative day with hydrocortisone (20 mg/ day) and testosterone heptylate (250 mg/3 weeks). Nifedipine (30 mg/ day) was maintained for 1 yr, and then all antihypertensive medications were stopped (Table 1) .
Postoperative evolution was marked by normalization of renin and near normalization of S and DOC levels. The levels of these compounds remained above normal, however, indicating small rests of secreting adrenocortical tissue. Blood pressure progressively returned to normal and stayed at 120/80 mm Hg even after removal of nicardipine ( Table  1 ). The patient did not require mineralocorticoid replacement therapy to maintain normal renin and potassium levels. This is probably due to the fact that the patient was used to a high salt intake (which might have explained in part the severity of his hypertension) and that his DOC levels remained slightly elevated. Eighteen months after surgery a new echocardiogram showed regression of the concentric ventricular hypertrophy. Compliance with the substitutive therapy remained excellent, and the patient expressed a very high degree of satisfaction with the adrenal surgery. Despite quitting smoking, the patient's weight was stabilized at 58 kg.
On macroscopic examination, the total weight of the glands was 30 g, and their usual shape was deformed by numerous nodules with diameters up to 2 cm ( H]F (100 Ci/mmol) were purchased from the Radiochemical Center (Amersham Pharmacia Biotech, Aylesbury, UK). Rabbit polyclonal antibodies to bovine 3␤-hydroxysteroid dehydrogenase (3␤HSD), CYP11A1 (9), and CYP11B (10) were developed in the laboratory using purified proteins from bovine adrenal cortex.
Cell isolation and culture
Adrenocortical cells were obtained as described previously (11) by enzymatic digestion of 5 g of one hyperplastic adrenal followed by Samples were taken at 0800h in either the supine or upright position as mentioned. Last administration of prednisone (preoperative) or hydrocortisone (postoperative) was 24 h before sampling. Preoperatively the patient was receiving potassium supplementation and 100 mg/day nicardipine, blood pressure was 170/100 mm Hg. Spironolactone had been stopped 1 month before surgery because of poor tolerance. One week postoperatively the patient was receiving 30 mg/day nifedipine and no potassium supplementation, serum potassium was normal, and blood pressure was 130/80 mm Hg. Nifedipine was stopped 6 months later, and blood pressure remained at 120/80 mm Hg. Serum hormone levels were measured by RIA or immunoradiometric assays as described in Subject and Methods. purification on a Percoll gradient. Cells (3 ϫ 10 6 ) were obtained, seeded in multiwell dishes, and cultured for 24 h in Ham's F-12/DMEM containing 10% FCS with antibiotics, 10 mg/ml transferrin, 10 mg/ml insulin, and 10 Ϫ4 mol/L vitamin C. After 24 h of culture, the medium was changed for serum-free Ham's F-12/DMEM. Normal human adrenocortical cells were prepared using the same procedure with a fragment of histologically normal adrenal cortex adjacent to a nonsecreting adrenocortical adenoma.
Mitochondria
A piece of adrenal gland (2 g) was homogenized with a Teflon PotterElvejhem apparatus in 5 mmol/L Tris-HCl buffer (pH 7.4) containing 250 mmol/L sucrose. The supernatant resulting from an 800 ϫ g, 15-min centrifugation was centrifuged at 10,000 ϫ g for 15 min. The resulting mitochondrial pellet was washed in the same buffer and centrifuged at 10,000 ϫ g for 15 min.
Immunoblot analyses
Mitochondrial proteins were subjected to SDS-PAGE (10% polyacrylamide gel) and then transferred to nitrocellulose membranes. After transfer, the sheets were washed in phosphate-buffered saline (PBS) containing 0.1% (wt/vol) Tween-20 (TPBS), then incubated (1-12 h) with TPBS containing 5% (wt/vol) skim milk. Incubations with the antisera (10 l in 15 ml TPBS) were run for 2 h. After washing, the sheets were incubated with antirabbit IgG-horseradish peroxidase conjugate (BioRad Laboratories, Inc., Ivry sur Seine, France) for 1 h. The antigenantibody complex was revealed by enhanced chemiluminescence (Renaissance, NEN Life Science Products) or was visualized by incubation in 10 ml Tris-HCl buffer (50 mmol/L; pH 7.6) containing 6 mg 3,3Ј-diaminobenzidine tetrachloride and 10 l H 2 O 2 (30%).
Hormone measurements
18-Hydroxycorticosterone, DOC, 18-hydroxydeoxycorticosterone, and aldosterone were measured in the patient's serum by RIA (12), using antisera that were gifts from Dr. Aupetit (Hopital Pitie-Salpetriere, Paris, France). Cortisol and S were measured by RIA either in the patient's serum or in the cell medium after separation on a Celite column to protect against cross-reactivity of F antiserum with S. Cortisol antiserum was obtained from Endocrine Sciences, Inc. (Calabasas Hills, CA); S antiserum was developed in the laboratory. Plasma ACTH-(1-39) and active renin were measured by immunoradiometric assay with commercial kits from Nichols Institute Diagnostics (San Juan Capistrano, CA) and Cis-Bio (Les Ulis, France), respectively. 
Enzymatic activities
DNA amplification and sequencing
Peripheral blood samples of the index case were obtained with informed consent according to our institutional guidelines. On the contrary, the living relatives (mother and three sisters) of the index case refused to give blood samples, which prevented us from performing a familial genetic analysis. Genomic DNA was prepared as previously described (15) . Selective amplification of the CYP11B1 gene was performed in five fragments by PCR in 100 L reactions containing 750 ng genomic DNA, 500 mol/L of each primer, 200 mol/L of each deoxy-NTP, 2.5 U Taq polymerase, and 1 ϫ Taq reaction buffer (Eurobio, Les Ulis, Paris). The concentration of MgCl 2 was 1.5 mmol/L, except for the exon 6 -7 fragment (2 mmol/L). The PCR program on a GeneAmp 9600 Perkin-Elmer Corp. thermocycler (Norwalk, CT) was 95 C for 5 min, followed by 30 cycles of 15 s at 95 C, 15 s at 56 C (60 C for exons 7-9), and 20 s at 72 C, with a 72 C final extension for 10 min in the last cycle. The oligonucleotide primers were located in the introns, except for the reverse primer used to amplify exons 7-9, and their sequences as follows: exons 1-2, 5Ј-TGACGTGATCCCTCTCGAAG-3Ј (forward) and 5Ј-AAGCTTTTCCTGCCTCTCTCGCC-3Ј (reverse); exons 3-5, 5Ј-TAGAC-CTGAGTGGCCTTTGTC-3Ј (forward) and 5Ј-TCACATCACAATC-CCAAGTAAG-3Ј (reverse); exons 6 and 7, 5Ј-GGGGTTTGGATGGGCAT-TAGGAT-3Ј (forward) and 5Ј-ACCCAGAGAGTAGAGGAACACG-3Ј (reverse); and exons 7-9, 5Ј-CGACCTGGGCTTCCCATGGATCT-3Ј(forward), 5Ј-CTGGGACCCTGGGTGCAGAGACG-3Ј (reverse). Mutation detection was performed by fluorescent sequencing with dye primer chemistry as described previously (16) .
Mutations and polymorphisms are designated according to the convention of Beaudet and Tsui (17) as modified by Antonarakis (18) . Numbering of the nucleotides is based on the gene sequence reported by Mornet et al. (19) , excluding the introns and using as 1 the first nucleotide of the initiating ATG codon.
RNA extraction and RT-PCR
Total RNAs were purified from adrenal tissue as previously described (11) . The first complete cDNA of the CYP11B1 gene has been generated using the Titan one-tube RT-PCR method (Roche Molecular Biochemicals), using primers located in the translated region of exons 1 and 9: 5Ј-TTTGGATCCACCATGGCACTCAGGGCAAAGGCA-3Ј (forward) and 5Ј-GGGGAATCTAGAGACGTGATTAGTTGATGGC-3Ј (reverse). Complete sequencing of this cDNA was performed using six primers, including the two described above. To demonstrate the presence of one mRNA, a partial cDNA encompassing the two polymorphisms, 225G3 A and 246T3 C, was generated for sequencing by RT-PCR methods using the same forward primer and a reverse primer overlapping the border between exons 2 and 3.
Ribonuclease protection assay
Probes for human P450aldo, P450c11, and actin were cloned in pCRII and were a gift from W. Freige and W. E. Rainey (20, 21) . The linearized plasmids were used in a transcription reaction with [␣-32 P]CTP and T7 RNA polymerase using the MAXIscript in vitro transcription kit (Ambion, Inc., Austin, TX). The ribonuclease protection assay was performed using the RPA II Ribonuclease Protection Assay kit (Ambion, Inc.). Protected RNA species were resolved by electrophoresis on a denaturing acrylamide (5%)-urea (8 mol/L) gel. A 32 P-labeled DNA ladder was used to determine the size of the protected fragments. pUC19 was digested with Sau3A1, then end labeled with [ 32 P]deoxy-CTP and 1 U Klenow DNA polymerase. Radiolabeled bands were visualized and quantitated by direct scanning with a ␤-imager using ImageQuant software (PhosphorImager, Molecular Dynamics), with the actin signal as the reference.
Results
In vitro steroidogenesis of the patient's adrenocortical cells and mitochondria
Production of F and S was measured in the cells under basal conditions or during a 2-h stimulation by ACTH. As expected, the patient's cells showed no measurable production of F, but had high basal and ACTH-stimulated productions of S. The cells were also incubated in the presence of B. Aldosterone production was detectable, although weaker, than the production of normal adrenocortical cells (Fig. 2A) . Incubation of the patient's adrenocortical mitochondria with
14 C]DOC also showed no production of F and B, respectively (Fig. 2, B and C) , demonstrating the absence of detectable 11␤-hydroxylase activity. However, the patient's mitochondria showed weak production of 18-hydroxycorticosterone (Fig. 2C) . Both mitochondrial side-chain cleavage activity (patient, 2 Ϯ 0.3 pmol/min⅐mg protein; normal adrenal, 1.15 Ϯ 0.3 pmol/min⅐mg protein) and 3␤HSD/isomerase activity (patient, 49 Ϯ 5 pmol/min⅐mg protein; normal, 46 Ϯ 3 pmol/min⅐mg protein) were similar to those of normal adrenal mitochondrias.
CYP11B1 genomic DNA sequencing
Sequencing of the patient's DNA revealed two new base substitutions in the CYP11B1 genomic sequence: 954 G3 C and IVS8 ϩ 4A3 G (Fig. 3) . The G to C substitution at the last nucleotide of exon 5 does not change the predicted amino acid, threonine 318. The A to G substitution at the fourth nucleotide of intron 8, termed either 1398 ϩ 4A3 G or IVS8 ϩ 4A3 G, is located two nucleotides downstream of the 5Ј-GT splice donor site. These substitutions, the last nucleotide G of an exon and the fourth nucleotide A of an intron, have two properties in common: they are highly conserved in higher eukaryotes (80.3% and 72%, respectively), and they belong to the consensus sequence for the 5Ј-splicing donor site (exon G GUAA intron) (22) . In addition, two frequent 14 C]DOC (C), and the steroids produced were separated by TLC. Nonradioactive steroids corresponding to each of the expected radioactive steroid products were also spotted. X, Unidentified compounds.
polymorphisms, 225G3 A (exon 1) and 246T3 C (exon 2), were found in the patient's DNA. As the family members refused to participate in a genetic analysis, it was not possible to study the segregation of the two CYP11B1 alleles.
Adrenal CYP11B1 mRNA expression and cDNA sequence
To understand the mechanisms by which the two genomic DNA base substitutions could account for the lack of 11␤-hydroxylase activity, mRNA was extracted from the patient's adrenal and reverse transcribed into cDNA, and CYP11B1 cDNA were amplified by PCR. A normal adrenal and an adrenal originating from a patient with ACTH-dependent Cushing's syndrome were used as controls. Separation of the PCR products on an agarose gel showed that both the normal adrenal and the Cushing adrenal had three cDNA bands, including one of the expected size for the full CYP11B1 cDNA and two smaller ones. In contrast, the patient's adrenal showed only the smallest band (Fig. 4A) . Sequence analysis showed that this band corresponded to a CYP11B1 cDNA that lacked exon 8 and did not bear the 954 G3 C base substitution at exon 5 (Fig. 4B) . To demonstrate the presence of one mRNA, a partial cDNA encompassing the two polymorphisms, 225G3 A and 246T3 C, was generated for sequencing by RT-PCR methods using the same forward primer and a reverse primer overlapping the border between exons 2 and 3. Neither of the two polymorphisms was found in the patient's cDNA. Ribonuclease protection assay was then performed using specific CYP11B1 and CYP11B2 probes located in the untranslated region of exon 9, in which there is less homology between the two sequences (20) . Expression of CYP11B1 mRNA was detected in the patient's adrenals (ϳ30% of the expression in normal cells), confirming expression of a CYP11B1 allele containing exon 9. Expression of CYP11B2 mRNA, which was high in an aldosterone-producing tumor used as a control, was below the limit of detection in the patient's cells, as it was in normal cells (Fig. 5) .
Adrenal expression of CYP11B immunoreactivity
To test the hypothesis that the two genomic DNA mutations resulted in the expression of only a truncated protein lacking   FIG. 3 . Sequencing of CYP11B1 genomic DNA from a patient with steroid 11␤-hydroxylase deficiency. Genomic DNA was extracted from leukocytes of the patient with steroid 11␤-hydroxylase deficiency and from a normal control. The DNA were amplified by PCR with CYP11B1-specific primers and sequenced on an automated sequencer.
FIG. 4. Analysis of adrenal CYP11B1
mRNA by RT/PCR (A) and sequencing (B). RNA were prepared from the patient's adrenals, from a normal adrenal (N), and from an ACTH-dependent Cushing's syndrome adrenal (Cushing). A, The mRNA were reverse transcribed into cDNA, amplified by PCR, and migrated on an agarose gel. B, The patient's cDNA was sequenced on an automated sequencer.
exon 8, analysis of CYP11B1 immunoreactivity was then performed on the patient's adrenal mitochondria using a bovine anti-CYP11B serum that also recognizes human CYP11B1 and CYP11B2. Cytochrome P450 scc (CYP11A1) and 3␤HSD immunoreactivities were assayed as controls. The patient's mitochondria showed normal cytochrome CYP11A1 and 3␤HSD immunoreactivities, but almost no CYP11B immunoreactivity at the normal apparent size (51 kDa). There was instead weak CYP11B immunoreactivity corresponding to a protein of about 43 kDa, consistent with the size of an exon 8 truncated CYP11B1 protein (Fig. 6) . The very weak CYP11B immunoreactive band that could be detected at the normal size might be related to the very low expression of a normal CYP11B1 protein, to the expression of CYP11B2, or to the low cross reactivity of the anti-CYP11B serum toward CYP11A1.
Discussion
Laparoscopic bilateral adrenalectomy is not an established treatment for patients with steroid 11␤-hydroxylase deficiency and has rarely been reported in this disease (8) . The reason for this is that glucocorticoid-suppressive treatment is supposedly effective in correcting the two major problems linked to steroid 11␤-hydroxylase deficiency: overproduction of adrenal androgens and mineralocorticoids. However, due to the rarity of the disease there are little data to document the long-term efficacy and potential side-effects of this treatment. As suppressive therapy for congenital adrenal hyperplasia was only discovered in 1950, there are no data for patients treated for more than 50 yr. There are, however, several reports that document problems in patients treated for steroid 11␤-hydroxylase deficiency, including advanced puberty in girls, pubertal gynecomastia in boys, and short final height and cardiovascular complications in both sexes (23, 24) . Extremely severe cardiovascular complications have been reported in patients who were proposed for suppressive treatment but did not accept it (4).
The patient reported here illustrates the difficulties with suppressive therapy and the potential interest of adrenalectomy. In childhood, suppressive therapy was marked by periods of either undertreatment with poor control of hypertension or overtreatment and appearance of Cushingoid features. The very short final stature is the combined result of androgen-related precocious bone maturation, supraphysiological glucocorticoid administration, and the female genetic sex. During adulthood, compliance was very poor, as suppressive treatment was dropped because it was felt to be responsible for weight gain. As a result the patient developed pronounced left ventricular concentric hypertrophy and finally presented with central retinal vein occlusion, for which hypertension is a well established major risk factor and the only one present in this patient (25) . Restoration of suppressive treatment was again rapidly confronted with the fact that effective suppression of mineralocorticoid secretion required doses of glucocorticoid that induced Cushingoid features, especially weight gain. It should be stressed that the macronodular hyperplasia that had developed during the years of unsuppressed ACTH secretion probably made suppressive treatment even more difficult even though no truly autonomous secretion had developed.
A comment is necessary on the decision, made in the early 1950s, to raise this pseudohermaphroditic female patient as a male and perform ovariectomy. This strategy, which resulted in infertility and had major consequences on the patient's social and sexual life, is now generally abandoned in favor of surgical reconstruction of the abnormal female external genitalia (5, 26) . Here, one can assume that the male phenotype helped the patient to drop suppressive treatment, as it allowed him to escape the symptoms of unsuppressed adrenal androgen production.
This report and others (8, 23, 24, 27) question the feasibility and effectiveness of suppressive treatment in preventing the long-term consequences of exposure to androgen and mineralocorticoid excess. Hence, the question of adrenalectomy as an alternative treatment deserves the same attention in steroid 11␤-hydroxylase deficiency as in 21-hydroxylase de- ficiency (7) . Regarding this debate there are some differences between the two main causes of CAH. In steroid 11␤-hydroxylase deficiency the patients are not naturally deficient in mineralocorticoid, so noncompliant patients are generally not exposed to the threat of acute adrenal insufficiency; salt loss is rare and has been described mainly in patients after suppressive treatment, who can develop atrophy of the fascicula-reticularis zone (29 -31) . This point would argue against adrenalectomy in poorly compliant 11␤-hydroxylase-deficient patients. However, poorly compliant 11␤-hydroxylase-deficient patients are precisely those who may benefit more from adrenalectomy; most of them will eventually develop moderate to severe hypertension, and because of long-term poor suppression of ACTH, they will develop a marked degree of nodular hyperplasia that makes suppressive therapy even more difficult. Therefore, in discussing adrenalectomy in a poorly compliant, steroid 11␤-hydroxylase-deficient patient, one needs to thoroughly analyze the reason for poor compliance. Here, we believed that the main reason was the responsibility of suppressive therapy for the appearance of Cushingoid features, a problem unlikely to happen with substitutive therapy. So we hypothesized that there will not be compliance problems with substitutive therapy. This proved, to date, to be correct.
Molecular genetics aspects of congenital hyperplasia are relevant to the decision for adrenalectomy. In steroid 21-hydroxylase deficiency, Ritzen and Wedell advocate surgical treatment instead of suppressive therapy for girls harboring mutations that are known to annihilate 21-hydroxylase activity (7). Patients with the classical form of steroid 11␤-hydroxylase deficiency are also believed to bear mutations that totally destroy the expression or activity of CYP11B1 (5). However, in the patient reported here, this was unclear, as analysis of genomic DNA had shown two previously undescribed base substitutions whose significance remained elusive, as the 954 G3 C transversion in exon 5 is conservative, and the IVS8 ϩ 4A3 G mutation is intronic (intron 8). Adrenal tissue obtained at surgery showed that these substitutions were deleterious. Sequencing of adrenal CYP11B1 cDNA showed that it was shorter due to the absence of exon 8 and that it lacked exon 5 954 G3 A mutation and the two polymorphisms. This indicated that the intron 8 mutation (IVS8 ϩ 4A3 G) and the exon 5 954 G3 A mutation were on different alleles. One CYP11B1 allele carried the intron 8 mutation (IVS8 ϩ 4A3 G) in the 5Ј-splice donor site, and this mutation should be responsible for the skipping of exon 8. The other allele carried exon 5 954 G3 A mutation and the two polymorphisms, and this allele was not expressed. As exon 8 encodes for the binding region of the heme prosthetic group necessary for the enzymatic activity (32), the truncated P450c11 protein is not functional, as suggested by in vitro studies. The reason for the loss of the other allele remains somewhat speculative. Codon 318 has been reported to be the site of different mutations, T318M (953C3 T), T318R (953T3 G) (6, 33) . In our patient, the 954 G3 C transversion is conservative (T318T), but it is located on the last base of exon 5, which is part of the splicing donor site. A homozygous conservative mutation in the same codon, 954G3 A, has actually been described in a patient with steroid 11␤-hydroxylase deficiency, and it was suggested to affect the correct splicing of CYP11B1mRNA. However, this patient also carried a nonconservative homozygous mutation C494F in exon 9 that could be sufficient to explain his phenotype (34) . Several mutations of the last nucleotide have been reported as 5Ј-splice site mutations (35) . The major consequence of these mutations was often the skipping of the entire preceding exon and sometimes the use of cryptic donor sites downstream in the exon. Sequencing of CYP11B1 cDNA seems to rule out these hypotheses. Nevertheless, as skipping of exon 5 should create a frame shift with a codon stop at 329, it is possible that the aberrant splicing due to this 954 G3 C mutation generates an unstable mRNA undetectable by RT-PCR methods. However, we cannot exclude the possibility that the allele carrying the exon 5 mutation might also carry another mutation in the promoter region of CYP11B1 that would be responsible for the loss of expression of this allele.
In conclusion, we have described two new mutations in CYP11B1 in a patient with severe steroid 11␤-hydroxylase deficiency. These mutations are presumably responsible for the loss of 11␤-hydroxylase activity, although they do not change, at first glance, the predicted amino acid sequence coded by the mutated alleles. These severe mutations were described in a patient who illustrates the difficulties in maintaining an effective suppressive therapy until adulthood and raises the question of adrenalectomy as an alternative. It should be stressed that adrenalectomy in adulthood for CAH is a decision that in a way negates the previous therapeutic choices made in infancy by the medical team and endorsed by the patient for many years. Therefore, one can hope that further clinical and genetic studies will help define which patients with steroid 11␤-hydroxylase deficiency will most benefit from adrenalectomy in early infancy.
